TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15220247
Drug: Fixed-dose trandolapril-verapamil
Normalized name: trandolapril / verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose trandolapril-verapamil (FDTV) 2 mg trandolapril/180 mg verapamil once daily
Study: 15220247
Drug: Fixed-dose trandolapril-verapamil
Normalized name: trandolapril / verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose trandolapril-verapamil (FDTV)
Study: 2802896
Drug: Aspartame (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (75 mg/kg per day, capsule form, three times daily for 24 weeks)
Study: 2802896
Drug: Placebo (capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (capsule form, three times daily for 24 weeks)
Study: 31546498
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: Low parameters (AFR = 20 cc/min, BH = 90 cm, vacuum = 400 mmHg)
Study: 31546498
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: High parameters (AFR = 40 cc/min, BH = 110 cm, vacuum = 650 mmHg)
Study: 28599034
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) treatment, moleskin and Tegaderm®
Study: 28202770
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) treatment
Study: 16490895
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing (sugarless gum 3 times daily for 1 hour each until discharge)
Study: 11323373
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume breathing (TVB) for 3-5 min at 5, 7, and 10 L/min fresh gas flow (FGF)
Study: 11323373
Drug: Four deep
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four deep breaths (DB) in 0.5 min at 5, 7, and 10 L/min FGF
Study: 11323373
Drug: Eight deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight deep breaths (DB) in 1 min at 7 and 10 L/min FGF
Study: 11323373
Drug: Deep breathing
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep breathing extended to 1.5 and 2 min with 10 L/min FGF
Study: 11323373
Drug: Increasing FGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing FGF from 5 to 10 L/min
Study: 29393208
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone dose adjustments to reach plasma R-methadone levels (80-250 ng/mL)
Study: 20795751
Drug: Menveo vaccine
Normalized name: Menveo Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menveo vaccine
Study: 16881934
Drug: Prolonged thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged thromboprophylaxis with dalteparin (5000 IU once daily for 28 days)
Study: 12832673
Drug: gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemifloxacin 320 mg once daily for 5 days
Study: 12832673
Drug: clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin 500 mg twice daily for 7 days
Study: 9072891
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of antioxidants in combined treatment of schizophrenic patients
Study: 3921278
Drug: Diltiazem (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (up to 360 mg daily)
Study: 3921278
Drug: Propranolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol plus maximum tolerated dose of diltiazem
Study: 26726854
Drug: Brief positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief positive psychotherapy plus usual treatment
Study: 22795046
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy coupled with cognitive behavioral therapy (MET‐CBT)
Study: 9266876
Drug: Cefuroxime, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime, 1.5 g IV tid for 48 to 72 h followed by oral cefuroxime axetil, 500 mg bid for 7 days
Study: 9266876
Drug: Cefuroxime, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime, 1.5 g IV bid for 48 to 72 h followed by oral cefuroxime axetil, 500 mg bid for 7 days
Study: 8302152
Drug: Continuous succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous succinylcholine infusion
Study: 8302152
Drug: Single-dose technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose technique
Study: 22889466
Drug: Intra-umbilical injection
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-umbilical injection of oxytocin (50 IU diluted with normal saline to a total volume of 30 mL)
Study: 22889466
Drug: Intra-umbilical injection
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-umbilical injection of normal saline (30 mL)
Study: 21277062
Drug: midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam and 1‐mg/kg tramadol
Study: 21277062
Drug: midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam and 1‐μg/kg fentanyl
Study: 19843062
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (education on disease state, medications, and breathing techniques)
Study: 16488953
Drug: NSAID ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID ophthalmic solution (sodium 2‐amino‐3‐(4‐bromobenzoyl) phenylacetate sesquihydrate) administered for 12 weeks
Study: 16488953
Drug: Sodium hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronic acid ophthalmic solution (control group) administered for 12 weeks
Study: 11128921
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (GP-)
Study: 9304635
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of oral ketorolac tromethamine (KT) 2 hours prior to surgery
Study: 9304635
Drug: 0.03% flurbiprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% flurbiprofen sodium (FS) topical solution
Study: 9304635
Drug: Topical normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical normal saline
Study: 8141723
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of heparin
Study: 3087694
Drug: Norplant (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norplant (six capsules)
Study: 30626347
Drug: Thrice-weekly hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly hemodialysis regimen
Study: 24490949
Drug: Ginger (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (1600 mg daily for 12 weeks)
Study: 24490949
Drug: Placebo (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1600 mg wheat flour daily for 12 weeks)
Study: 16198982
Drug: 5-HT-receptor antagonists
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT-receptor antagonists (standard dose, IV/oral)
Study: 9589243
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg daily for 8 weeks
Study: 7998769
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (twice a week for 3 weeks then once a week for 3 weeks)
Study: 7998769
Drug: Immune globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune globulin infusion (0.4 gm/kg once a week for 3 weeks, then 0.2 gm/kg once a week for the next 3 weeks)
Study: 7998769
Drug: Immune globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune globulin infusion
Study: 2897788
Drug: Glutamic acid
Normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamic acid 500 mg orally three times daily plus vincristine 1.0 mg/m2 weekly for six doses
Study: 2897788
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus vincristine 1.0 mg/m2 weekly for six doses
Study: 29017421
Drug: Comprehensive medication
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medication reviews (CMRs) by intervention pharmacists
Study: 26927249
Drug: Low-dose add-back
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose add-back therapy (estradiol valerate 1 mg and medroxyprogesterone acetate 2.5 mg, once a day)
Study: 26927249
Drug: Regular-dose add-back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular-dose add-back therapy (estradiol valerate 1 mg and medroxyprogesterone acetate 2.5 mg, twice a day)
Study: 26927249
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (low dose and regular dose)
Study: 24690416
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Atomoxetine (ATX)
Study: 24690416
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 10 Hz rTMS and 60 mg ATX
Study: 16211736
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg and paracetamol 1.5 g
Study: 16211736
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and paracetamol 1.5 g
Study: 8658044
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (21/min by nasal prongs)
Study: 8658044
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oxygen therapy)
Study: 1610863
Drug: Double-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug therapy (cyclosporine and azathioprine)
Study: 1610863
Drug: Double-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug therapy
Study: 6734370
Drug: Diltiazem 90
Normalized name: diltiazem 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 90 mg QID
Study: 6734370
Drug: Diltiazem (90,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90, 120, 150 mg)
Study: 24626733
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with 14 mL of 0.75% ropivacaine plus 4.0 mcg/kg of clonidine
Study: 24626733
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with 14 mL of ropivacaine 0.75 % plus 0.0266 mL/kg of 0.9% saline solution
Study: 23092451
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation of 2800 μg folic acid
Study: 23092451
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation of 60 mg iron and 2800 μg folic acid
Study: 23092451
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation of multiple micronutrients (MM)
Study: 21053992
Drug: Linagliptin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 0.5 mg intravenously
Study: 21053992
Drug: Linagliptin 2.5
Normalized name: linagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 2.5 mg intravenously
Study: 21053992
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg intravenously and 10 mg oral tablet (crossover)
Study: 21053992
Drug: Linagliptin 10
Normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 10 mg intravenously
Study: 11390726
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (250 mg iron diluted in 100 ml normal saline given over 60 min once per month)
Study: 11390726
Drug: Iron gluconate
Normalized name: Iron Gluconate 27mg Tablet
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron gluconate (62.5 mg iron given once per week in a slow push injection)
Study: 9422429
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral ganciclovir (1000 mg p.o. t.i.d.; n=19)
Study: 9422429
Drug: Deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred therapy (Acyclovir 200 mg p.o. b.i.d.; n=23)
Study: 8388275
Drug: Rhesus-human reassortant
Normalized name: human-bovine reassortant rotavirus strain G4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus-human reassortant tetravalent rotavirus vaccine (4 x 10^4 plaque forming units)
Study: 8388275
Drug: Rhesus-human reassortant
Normalized name: human-bovine reassortant rotavirus strain G4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus-human reassortant tetravalent rotavirus vaccine
Study: 2834480
Drug: PK 10169
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK 10169 at 0.75 mg/kg
Study: 2834480
Drug: PK 10169
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK 10169 at 1 mg/kg
Study: 2834480
Drug: PK 10169
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK 10169 at 1.25 mg/kg
Study: 23614849
Drug: Diuretic added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic added during first month
Study: 19095506
Drug: Ketamine-clonidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine-clonidine infusion before anesthesia induction
Study: 12972745
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine analgesia
Study: 7038157
Drug: Propranolol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (180 or 240 mg/day)
Study: 28648913
Drug: Oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10 mg extended release b.i.d)
Study: 28648913
Drug: Venlafaxine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (37.5 mg extended release b.i.d)
Study: 26556692
Drug: One year
Normalized name: Annovera 0.15 MG / 0.013 MG per 24HR One Year Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: One year of free school fruit (daily one piece of fruit or vegetable)
Study: 19894656
Drug: Treatment based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment based on first visit
Study: 14628989
Drug: Paroxetine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (any dose)
Study: 11405344
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human alpha‐Gal A (r‐halphaGal A) replacement therapy for Fabry disease
Study: 9404906
Drug: Cefixime (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (10 mg/kg to 12 mg/kg per day in two divided doses)
Study: 9404906
Drug: Chloramphenicol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (100 mg/kg daily in four divided doses)
Study: 8388231
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus verapamil (480 mg day‐1 for 3 days prior to chemotherapy)
Study: 3317054
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg every six hours for 24 hours)
Study: 28838583
Drug: Oral Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Aripiprazole 10 to 30 mg/d
Study: 26614965
Drug: PrEP with
Normalized name: Alcohol Prep with Benzocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP with oral emtricitabine and tenofovir disoproxil fumarate
Study: 23335369
Drug: R-CHOP treatment
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP treatment with MYC, BCL2, and BCL6 rearrangements and protein expression analysis
Study: 21569539
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anti-epileptic drugs)
Study: 16543098
Drug: Low-dose intrathecal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intrathecal morphine (0.2 mg)
Study: 14597934
Drug: β-blocker therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker therapy for CHF
Study: 10912311
Drug: Non-hormonal and
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-hormonal and hormonal agents
Study: 9238868
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Interclean (ID2)
Study: 29867230
Drug: Atezolizumab (monotherapy)
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab (monotherapy)
Study: 25990196
Drug: Focal muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal muscle vibration (FMV) treatment according to the 'repeated muscle vibration' protocol
Study: 19058081
Drug: Helix aspersa
Normalized name: Helix aspersa specific immunoglobulin E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helix aspersa extract cream applied twice daily for a maximum period of 14 days or until full epithelialization
Study: 19058081
Drug: Moist exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moist exposure burn ointment (MEBO)
Study: 15643550
Drug: BSE-018 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSE-018 with a high-fat meal (treatment B)
Study: 15643550
Drug: BSE-018 in
Normalized name: NUTR SUPL COMPLEAT ORGANIC PLANT BSE LIQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSE-018 in the fasted state (treatment A)
Study: 11441425
Drug: Butorphanol (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (0.5, 1, and 2 mg/70 kg)
Study: 11441425
Drug: Morphine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2.5, 5, and 10 mg/70 kg)
Study: 11441425
Drug: Nalbuphine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (2.5, 5, and 10 mg/70 kg)
Study: 11441425
Drug: Pentazocine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (7.5 and 15 mg/70 kg)
Study: 9075778
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 350 mg/m2 as intravenous bolus injection plus folinic acid (FA) 200 mg/m2 and interferon 5 x 10(6) U/m2 (regimen A)
Study: 9075778
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 500 mg/m2 as 2-hour infusion plus folinic acid (FA) 200 mg/m2 and interferon 5 x 10(6) U/m2 (regimen B)
Study: 16296710
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg once daily, adjusted to 10 mg after 2 weeks if necessary)
Study: 7019407
Drug: Oxacillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxacillin plus sisomicin and carbenicillin (treatment group)
Study: 30378465
Drug: High-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caffeine (10 mg/kg)
Study: 30378465
Drug: Moderate-dose caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose caffeine (4 mg/kg)
Study: 30378465
Drug: Repeated-dose caffeine
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated-dose caffeine (2 mg/kg before each match to a total of 10 mg/kg)
Study: 30378465
Drug: Selective caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective caffeine administration (6.16 ± 1.58 mg/kg)
Study: 30202508
Drug: Human agent
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human agent intervention
Study: 23797624
Drug: Clonidine 1
Normalized name: apraclonidine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1 μg/kg added to 2% lidocaine
Study: 20565999
Drug: Normal protein,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein, glycogen-lowering exercise (NP-g; 10, 60 and 30 En%)
Study: 20565999
Drug: High protein,
Normalized name: Ensure High Protein, Banana, Instant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein, carbohydrate-free (HP-0C) vs Normal protein (NP-g)
Study: 17629719
Drug: r-metHuGDNF via
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-metHuGDNF via continuous bilateral intraputaminal infusion
Study: 12805964
Drug: Quinfamide treatment
Normalized name: quinfamide
DrugBank: Quinfamide (DB12780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinfamide treatment (4.3 g/kg dose) administered at 3- or 6-month intervals.
Study: 9764615
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 microg every 4 hours)
Study: 9764615
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and Vaginal misoprostol
Study: 8181333
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium bromide added to albuterol sulfate
Study: 6831946
Drug: Albuterol alone
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol alone
Study: 30393104
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) at doses of 50 mg, 75 mg, and 100 mg, with training (reviewed IFU and shown how to inject)
Study: 30393104
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) at doses of 50 mg, 75 mg, and 100 mg, without training (only given IFU)
Study: 24781225
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with antidepressants and antipsychotics
Study: 22835841
Drug: Extinction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extinction treatment in three contexts (BCD)